Belgian tax instruments · for non-EU operators
Tax optimization is part of the EU entry, not an afterthought.
Belgium isn't usually the first jurisdiction non-EU operators think of for tax efficiency — that's a positioning failure of the Belgian system, not a substantive one. The Innovation Income Deduction, R&D Payroll Tax Exemption, and Holding Company regime stack into a tax surface that, for healthcare IP and R&D-heavy operators, rivals Ireland and beats most of the EU. We don't provide tax advice — we facilitate introductions to specialist Belgian counsel and integrate the tax pathway into the institutional sequence.
Quick answer · the headline number
3.75% effective tax rate on qualifying IP income via the Innovation Income Deduction (IID). 80% R&D payroll tax exemption on researchers' wages. 100% Dividend Received Deduction on qualifying participations. 30% expat regime for inbound researchers and executives. Belgium signs 70+ tax treaties including with the US, Canada, and Singapore — the non-EU jurisdictions most relevant to the operators Innovation Park serves.
Headline · IP & royalties
Innovation Income Deduction (IID)
3.75% effective
85% deduction on net qualifying IP income, dropping the effective corporate rate from 25% to ~3.75%. Applies to patents, supplementary protection certificates, copyrighted software, plant breeders' rights, orphan drug designations, and data exclusivity rights. Replaced the Patent Income Deduction in 2017 — broader scope, lower effective rate. Belgium's headline number to Ireland's 6.25% KDB.
R&D · most-used in absolute value
R&D Payroll Tax Exemption
80% partial
Companies employing qualifying R&D researchers can retain 80% of the withholding tax on their gross wages. For a medtech with 20+ qualifying researchers, this is typically the most valuable Belgian R&D incentive by absolute euro value — often exceeding the IID benefit in early years before IP income materializes.
R&D · capex side
R&D Investment Deduction
13.5–30.5%
One-time deduction on qualifying R&D investments (equipment, software, patents). Alternative: refundable R&D tax credit recoverable after 4 years if not absorbed. Stackable with the payroll exemption for the same project.
Holding · dividends
Dividend Received Deduction (DRD)
100%
100% exemption on qualifying inbound dividends from EU and non-EU subsidiaries (10%+ participation or €2.5M acquisition value, 12-month holding). Combined with the EU Parent-Subsidiary Directive and 70+ tax treaties, Belgium functions as a holding jurisdiction that competes directly with Luxembourg and the Netherlands.
Holding · capital gains
Capital Gains on Shares
10% standard
Since 1 January 2026, Belgium applies a 10% flat tax on share capital gains, with the first €10,000 of gains per year exempt and all pre-2026 gains grandfathered. Capital gains on qualifying corporate participations held through a Belgian company can still be fully exempt under the tightened participation-exemption conditions (≥10% or €2.5M, 12-month holding). For non-EU operators setting up a Belgian holdco above operating subsidiaries, this is the exit-side counterpart to the DRD.
Talent · inbound
Expat Tax Regime (since 2022)
30% exempt
Inbound researchers, executives, and specialists can receive up to 30% of gross remuneration as tax-exempt "cost proper to the employer" reimbursement (annual cap €90K). 5-year duration, extendable to 8. Replaced the old special tax regime in January 2022 — broader, more predictable, applies to inbound talent moving the operating team alongside the corporate vehicle.
Equity · structural
Incremental Notional Interest Deduction
~1–2% on new equity
Deduction calculated as a notional interest rate on incremental equity (post-2018 reform — now limited to net equity increase versus a 5-year reference base). Useful for equity-funded operating entities at scale; less impactful for early-stage. Floor-stop: ~25 bps in current low-rate environment.
Treaties · cross-border
Tax Treaty Network
70+ treaties
Belgium maintains a wide treaty network including with the United States, Canada, Singapore, Australia, Japan, Korea, UK, and every EU member. The US-Belgium treaty (renegotiated 2007, LOB clauses) and the Canada-Belgium treaty provide standard withholding tax reductions on dividends, interest, and royalties — matching or beating Irish equivalents for most cross-border flows.
How this combines with the institutional sequence
For a non-EU operator entering Europe through Belgium, the tax architecture sits under the institutional sequence — not parallel to it. The order is: FIT introduction → corporate vehicle structuring (with Belgian tax counsel) → VLAIO institutional onboarding → imec / EIT Health partnership → R&D BELSPO declaration → operating launch. Companies that get the tax structure right but skip the institutional sequence end up with a tax-efficient ghost ship. Companies that get the institutional sequence right but don't structure for IID and R&D payroll exemption leave 8–15% of EBITDA on the table.